In an exciting development for the field of surgical and robotic technology, the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) along with US Medical Innovations, LLC (USMI) have unveiled a revolutionary AI robotic system. Named the Canady Robotic AI Surgical System, it is a first-of-its-kind technology that leverages cold atmospheric plasma (CAP) to precisely target and eliminate microscopic tumor cells during surgical procedures, without causing harm to the surrounding healthy tissue.
Despite significant advancements in various treatment modalities including surgery, chemotherapy, radiation, immunotherapy, and biologic targeted therapy, microscopic residual disease persists in 5% to 65% of cases. This often leads to local regional recurrence and poor survival rates. The Canady Robotic AI Surgical System aims to address this issue, and will be showcased at the inaugural Global Surgical Oncology Summit in Jerusalem, Israel, from January 30 to February 2, 2024.
The Canady Robotic AI Surgical System is a technological marvel comprising several key components. These include a Motorized Positioning Arm, a Speech Recognition Canady Electrosurgical Generator known as ORLI™, a Controller for CAP Devices, and Robotic Assisted End Effectors. These components can be used in various surgical procedures including Open, Laparoscopic, Thoracoscopic, Endoscopic, and Mini-invasive surgeries.
The system also offers the surgeon a high degree of control and precision with 10 degrees of freedom. It features speech activation for robotic movements, AI-powered software programs, 3D navigational guided surgical planning, advanced contour tracking of the CAP beam, pre-programmed CAP dosimetry data for selectively targeting 32 cancer cell types, and a compact mobile design. This integration of electronics and programming languages in the system is a testament to how advancements in coding and computer technology can revolutionize medical procedures.
JCRI-ABTS has been granted five key U.S. patents for this innovative system. These patents cover the application of CAP technology to selectively target cancer cells, the integration of cold plasma and high-frequency electrosurgical system, the method for the use and treatment therapy, and the inclusion of AI-enabled speech recognition.
Taisen Zhuang, PhD, Chief Technology Officer, commented on the launch, stating that the Canady Robotic AI Surgical System has set a new benchmark for Robotic Cancer Surgery by merging AI technology and CAP. He added that this innovation enhances accuracy, precision, and safety in the operating room.
Saravana Murthy, PhD, Vice President of Research, stated that this smart integrated “System” is the world’s first therapy designed to selectively eliminate microscopic tumor cells at the surgical margins.
The CEO and Surgical Oncologist, Jerome Canady, MD, FACS, expressed that this technology will transform the landscape of the operating room. He added that data from a recent FDA Phase 1 Clinical Trial on Stage 4 Cancer Patients, combined with a decade’s worth of in-vitro translational molecular research data, have been incorporated into the Canady Robotic AI Surgical System.
This revolutionary development signifies a major step forward in integrating artificial intelligence and robotics in surgery. It highlights how advancements in electronics, computers, and programming languages can be harnessed to improve patient outcomes and save lives in the medical field. The Canady Robotic AI Surgical System is a testament to the power of innovation and the limitless potential of technology.
